Cao Jiajia, Zhang Yurong, Yue Ningning, Xiong Shuzhen, Zhang Shuni, Wu Chongyang
Department of Hematology, The Second Hospital of Lanzhou University, Lanzhou, China.
Front Oncol. 2025 Apr 29;15:1586842. doi: 10.3389/fonc.2025.1586842. eCollection 2025.
CD58 is a glycoprotein receptor widely distributed on histiocytes that binds to CD2, that takes part in constituting the Immunological Synapses (IS) and activating T/NK cells. Aberrant expression of CD58 has been demonstrated to exert a significant impact on the prognosis of hematological tumors, including leukemia and lymphoma. Furthermore, this aberrant expression has been associated with drug resistance and immune rejection in CAR cell therapy. In this article, we will explore the future of CD58 in hematological oncology by describing its function in immune cells, its impact on hematological oncology and immunotherapies such as CAR cell therapy.
CD58是一种广泛分布于组织细胞上的糖蛋白受体，它与CD2结合，参与构成免疫突触（IS）并激活T/NK细胞。已证明CD58的异常表达对包括白血病和淋巴瘤在内的血液肿瘤的预后有重大影响。此外，这种异常表达与嵌合抗原受体（CAR）细胞疗法中的耐药性和免疫排斥有关。在本文中，我们将通过描述CD58在免疫细胞中的功能、其对血液肿瘤学的影响以及诸如CAR细胞疗法等免疫疗法，来探索CD58在血液肿瘤学中的未来。
